GSK plc 6-K, filed Nov 14, 2022
GSK plc (GSK)
6-K
2022-11-14
For: 2022-11-14
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on November 14, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . ..X Form 40-F . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued:
11 November 2022, London UK
GSK provides an update on Zejula (niraparib) US prescribing
information
GSK plc
(LSE/NYSE: GSK) today provided an update that at the request of the
US Food and Drug Administration (FDA) it will restrict the
second-line maintenance indication for Zejula (niraparib) to only the
patient population with deleterious or suspected deleterious
germline BRCA mutations (gBRCAmut). The US first-line indication
of Zejula remains
unchanged for the maintenance treatment of adult patients with
advanced epithelial ovarian, fallopian tube, or primary peritoneal
cancer who have a complete or partial response to platinum-based
chemotherapy.
This decision follows an FDA review of the final overall survival
(OS) analysis of the ENGOT-OV16/NOVA phase III trial, which served as
the basis for the approval of the second-line maintenance
indication. In the final OS results from the
NOVA trial, the secondary endpoint of OS demonstrated a hazard
ratio (HR) of 1.06 (95% CI: 0.81-1.37) in the
non-gBRCAmut cohort.
NOVA is
a randomised, double-blind, placebo-controlled phase III trial of
niraparib, an oral, once-daily poly (ADP-ribose) polymerase (PARP)
inhibitor for the maintenance treatment of women with
platinum-sensitive recurrent ovarian cancer. The primary endpoint
of the NOVA study was progression-free survival (PFS), evaluated as
two independently powered cohorts (gBRCAmut and non-gBRCAmut); results demonstrated the
clinically meaningful and statistically significant benefit of
niraparib in both cohorts and across the HRD subgroups in the
non-gBRCAmut cohort. Secondary endpoints were safety and long-term
exploratory endpoints, including overall survival. GSK is in
ongoing discussions about these and other emerging OS data with
health authorities worldwide.
About ovarian cancer
Ovarian cancer is the eighth most common cancer in women
worldwide.[i] Despite
high response rates to platinum-based chemotherapy in the
front-line setting, approximately 85% of patients will experience
disease recurrence.[ii] Once
the disease recurs, it is rarely curable, with decreasing time
intervals for each subsequent recurrence.
About Zejula (niraparib)
Zejula is an oral, once-daily PARP
inhibitor currently being evaluated in multiple pivotal trials. GSK
is building a robust clinical development programme by assessing
activity across multiple tumour types and evaluating several
potential combinations of Zejula with
other therapeutics. The ongoing development programme includes
several combination studies, including the FIRST phase III trial
assessing niraparib in combination with
dostarlimab, a programmed death receptor-1
(PD-1)-blocking antibody, as a potential treatment for first-line
ovarian cancer maintenance and the phase III ZEAL trial assessing
niraparib in combination with standard of care for the maintenance
treatment of first line advanced non-small cell lung cancer. GSK
also is evaluating niraparib in HER2-negative BRCA-mutated or
triple-negative breast cancer.
Please see accompanying US Prescribing
Information.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore / Madeleine Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540 742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
[i] Worldwide Cancer Data. World Cancer Research
Fund.
https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data.
Updated January 10, 2022. Accessed July 2022.
[ii] Lorusso D, Mancini M, Di Rocco R, Fontanelli R,
Raspagliesi F. The role of secondary surgery in recurrent ovarian
cancer [published online August 5, 2012]. Int J Surg
Oncol. 2012.
doi:10.1155/2012/613980. Accessed September
2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
11, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|